Ab interno canaloplasty (ABiC)—12-month results of a new minimally invasive glaucoma surgery (MIGS)
- 73 Downloads
The aim of this study is to assess whether the ab interno canaloplasty is a reasonable minimally invasive method to lower significantly the IOP level and number of antiglaucomatous medication over a certain period of time in adult primary open angle glaucoma (POAG).
In this retrospective cohort outcome study, 36 eyes of 28 POAG patients (mean age 74.8 ± 9.3 years) with an IOP above target pressure were included. Ab interno canaloplasty (ABiC) was performed in all subjects (MEyeTech GmbH, Alsdorf, Germany) as sole procedure in pseudophakic eyes (n = 20) or in combination with cataract surgery in phakic eyes (n = 16). The intraocular pressure (IOP) and the number of glaucoma medication were assessed preoperatively, day 1, week 6, month 3, month 6, and month 12.
IOP decreased from 19.8 ± 4.1 to 13.8 ± 3 mmHg at 12 months follow-up (n = 21, p < 0.001). The IOP reduction showed significant results at all time points (1 day p < 0.001; 6 weeks p < 0.001; 3 months p < 0.001; 6 months p = 0.001; 12 months p < 0.001). Glaucoma therapy was stabilized at 2.1 ± 1.6 number of medications after 12 months postoperatively. There was no significant difference in the number of medication at 12 months follow-up (p = 1.0). No major perioperative complications can be reported.
The ABiC effectively lowers the IOP in POAG in the short term follow-up of 12 months. A reduction of glaucoma therapy cannot be achieved and should be discussed with the patients prior to surgery.
KeywordsGlaucoma Ab interno canaloplasty (ABiC) POAG MIGS
Compliance with ethical standards
The study complied with the ethical standards of the Declaration of Helsinki and followed the regulations of the Good Clinical Practice (GCP) Guidelines.
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 3.Burr J, Azuara-Blanco A, Avenell A (2005) Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev (2):CD004399Google Scholar
- 6.Shaarawy TGF, Sherwood M, World Glaucoma Association (2009) WGA guidelines on design and reporting of glaucoma surgical trials. Kugler Publications, The HagueGoogle Scholar
- 7.Richter GM, Coleman AL (2016) Minimally invasive glaucoma surgery: current status and future prospects. Clin Ophthalmol 10:189–206Google Scholar
- 8.Resende AF, Patel NS, Waisbourd M, Katz LJ (2016) iStent(R) trabecular microbypass stent: an update. J Ophthalmol 2016:2731856Google Scholar
- 10.Luebke J, Boehringer D, Neuburger M et al (2015) Refractive and visual outcomes after combined cataract and trabectome surgery: a report on the possible influences of combining cataract and trabectome surgery on refractive and visual outcomes. Graefes Arch Clin Exp Ophthalmol 253(3):419–423CrossRefGoogle Scholar
- 11.Le K, Saheb H (2014) iStent trabecular micro-bypass stent for open-angle glaucoma. Clin Ophthalmol 8:1937–1945Google Scholar
- 13.Fea AM, Belda JI, Rekas M et al (2014) Prospective unmasked randomized evaluation of the iStent inject ((R)) versus two ocular hypotensive agents in patients with primary open-angle glaucoma. Clin Ophthalmol 8:875–882Google Scholar
- 20.Khaimi MA (2015) Canaloplasty: a minimally invasive and maximally effective glaucoma treatment. J Ophthalmol 2015:485065Google Scholar
- 24.Cagini C, Peruzzi C, Fiore T, Spadea L, Lippera M, Lippera S (2016) Canaloplasty: current value in the management of glaucoma. J Ophthalmol 2016:7080475Google Scholar